Inmode Ltd Intrinsic Value Calculation – INMODE LTD’s Steady State Revenue Keeps Stock Fairly Valued, According to Evan Rodick.

Trending News ☀️

Inmode Ltd Intrinsic Value Calculation – INMODE ($NASDAQ:INMD): Evan Rodick’s article on InMode Ltd stock, “Steady State Revenue Fairly Valued,” can be found on Seeking Alpha. The article discusses the stock’s current valuation and how it is fairly valued relative to other stocks in its sector. InMode Ltd is a medical technology company that develops and manufactures minimally invasive and non-invasive aesthetic solutions. The company offers facial aesthetics, body shaping, energy-based treatment and hair removal products designed to meet the needs of both physicians and patients. In the article, Rodick states that InMode’s steady state revenue has been relatively stable over the past few years. He also points out that the company’s market capitalization is lower than that of its peers and that its current price-to-sales ratio is lower than the industry average.

He believes that this indicates that the stock is fairly valued relative to its peers. The article also states that InMode’s cash flow has been strong and that the company’s debt levels are low compared to other stocks in its sector. This, combined with its strong revenue growth and expanding global presence, makes it an attractive option for investors looking for a stock with a good track record and steady revenue growth. Overall, Rodick’s article emphasizes the fact that InMode Ltd’s steady state revenue is keeping the stock fairly valued and that it could be a good investment for those looking to diversify their portfolio. With its strong cash flow and growing presence in the medical technology sector, InMode Ltd could be a good long-term hold for investors.

Stock Price

INMODE LTD is a company that has seen its stock remain relatively consistent over the past few months. On Monday, INMODE LTD stock opened at $36.9 and closed at $36.5, down by 2.1% from prior closing price of 37.2. Despite this minor decrease, Evan Rodick, a financial analyst at the firm, believes that INMODE LTD’s steady state revenue has kept the stock fairly valued. Rodick noted that INMODE LTD’s steady state revenue has allowed the company to maintain a relatively stable stock price despite market volatility. He also pointed out that the company has managed to increase its revenue slowly and steadily over time, and that this trend was likely to continue in the near future. In addition to its steady state revenue, Rodick believes that INMODE LTD’s strong balance sheet has also contributed to its stock remaining fairly valued.

The company’s current liabilities are well below the industry average, and the company has managed to maintain a healthy cash flow. This, combined with its solid financial records and increasing revenue, has helped keep INMODE LTD’s stock fairly valued. Overall, Rodick believes that INMODE LTD’s steady state revenue and strong balance sheet have kept its stock fairly valued despite market volatility. With the company’s financial records in check and its revenue increasing, Rodick believes that INMODE LTD’s stock is in a good position for the foreseeable future. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Inmode Ltd. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Inmode Ltd. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Inmode Ltd. More…

Key Ratios Snapshot

Some of the financial key ratios for Inmode Ltd are shown below. More…

Analysis – Inmode Ltd Intrinsic Value Calculation

INMODE LTD is a public company which is currently traded at $36.5 a share. According to GoodWhale’s proprietary Valuation Line, the fair value of INMODE LTD is around $45.7. This implies that the company’s stock is currently undervalued by 20.1%. INMODE LTD’s fundamentals are analyzed by GoodWhale to determine the fair value of its shares. The fundamentals of the company include financial statements, balance sheets, income statements, cash flows, and other relevant information. By looking into these aspects, GoodWhale can determine whether the stock is currently being traded for more or less than its real worth. GoodWhale’s Valuation Line also takes into consideration the company’s growth potential as well as current market conditions. It looks at the company’s past performance and current operations to determine its future prospects and assess the true value of its stock. Given the current price of INMODE LTD stock, it appears that it is trading at a discount of 20.1%. This could be an opportunity for investors to buy the stock at a lower price and seek capital appreciation when the price of the stock reaches its fair value. More…

Peers

The market for aesthetic medical device is highly competitive with InMode Ltd. facing competition from Cutera Inc., Viveve Medical Inc., and Apyx Medical Corp. All four companies offer a range of products that target different areas of the body and address different aesthetic concerns. InMode Ltd. has a strong portfolio of products that are backed by clinical data and have a proven track record of safety and efficacy. The company’s products are also available in a variety of price points to meet the needs of different consumers.

– Cutera Inc ($NASDAQ:CUTR)

Cutera Inc is a medical device company that provides aesthetic treatments to patients worldwide. Founded in 1998, Cutera is headquartered in Brisbane, California, and has a market cap of 931.59M as of 2022. The company’s Return on Equity is -111.73%. Cutera’s products are used by physicians and other healthcare professionals to treat conditions such as wrinkles, acne, vascular lesions, and unwanted hair. The company’s products include laser and light-based devices, intense pulsed light devices, and radiofrequency devices.

– Viveve Medical Inc ($NASDAQ:VIVE)

Viveve Medical Inc. is a medical technology company that focuses on the treatment of female intimate health conditions. The company’s flagship product is the Viveve System, which is used to treat vaginal laxity, the condition where the vaginal walls become stretched and loose. The Viveve System uses radiofrequency energy to heat tissue and stimulate collagen production, which results in tighter, healthier tissue.

Viveve Medical Inc has a market cap of 6.19M as of 2022. The company’s Return on Equity is -179.17%. The company’s flagship product is the Viveve System, which is used to treat vaginal laxity. The Viveve System uses radiofrequency energy to heat tissue and stimulate collagen production, which results in tighter, healthier tissue.

– Apyx Medical Corp ($NASDAQ:APYX)

Apyx Medical Corp is a medical device company that develops, manufactures, and markets radiofrequency (RF) products for the global surgical market. The company’s products include the Renuvion System, a minimally invasive RF technology for tissue remodeling and tightening, and the J-Plasma System, a next-generation plasma-based technology.

Apyx Medical Corp has a market cap of 149.01M as of 2022, a Return on Equity of -22.62%. The company develops, manufactures, and markets radiofrequency (RF) products for the global surgical market. The company’s products include the Renuvion System, a minimally invasive RF technology for tissue remodeling and tightening, and the J-Plasma System, a next-generation plasma-based technology.

Summary

Investing analysis of INMODE LTD indicates that the company’s steady state revenue is enough to keep its stock fairly valued. This assessment was made by Evan Rodick, an expert in the field, and suggests that investors could benefit from investing in INMODE LTD. The company has performed well overall, which is reflected in a good share price and its market capitalization. This analysis suggests that investors should consider investing in INMODE LTD, as the stock is fairly valued given its current revenue.